ZTS
Zoetis Inc.
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · US
$79.59
+0.26%Oct 15, 2026, 02:45 UTC
ROY MORGAN RESEARCH LTD's annual farmer survey named Zoetis Inc., Bendigo and Adelaide Bank, GRAINCORP LIMITED, Meat & LIvestock Australia, and Nutrien Ltd. as repeat winners in their respective agribusiness brand categories.
Source:Oct 13, 2026, 11:41 UTC
Zoetis appointed Iris Knobloch as a director, effective December 1, 2026.
Oct 9, 2026, 23:15 UTC
Zoetis Inc. shares closed at $74.81, up 2.37% from the previous trading day.
Source:Oct 8, 2026, 20:15 UTC
Zoetis Inc. declared a fourth-quarter 2026 dividend of $0.53 per share, payable on December 1, 2026, to shareholders of record on October 30, 2026.
Source:Oct 6, 2026, 11:30 UTC
Zoetis announced a new peer-reviewed laboratory study showing Simparica Trio protected three times more dogs from infection with a resistant heartworm isolate than NexGard Plus.
Source:Sep 24, 2026, 23:16 UTC
Zoetis (ZTS) shares closed at $70.27, down 1.87% from the previous trading day.
Source:Sep 21, 2026, 01:15 UTC
Zoetis unveiled a new interactive exhibit space in the Coliseum Lower Level at the 2026 World Dairy Expo, featuring Dairy On Stage talks, the Milky Whey Lounge and the Born of the Bond wall.
Source:Sep 18, 2026, 23:15 UTC
Zoetis (ZTS) shares closed at $71.40, down 2.22% from the prior trading session.
Source:Sep 2, 2026, 23:59 UTC
The U.S. Food and Drug Administration published in the Federal Register three Emergency Use Authorizations for animal drugs to treat or prevent New World screwworm, including the first injectable product listing deer, issued to Zoetis, Felix Pharmaceuticals, and Alberta Vet Labs.
Source:Aug 13, 2026, 17:11 UTC
Zoetis received emergency use authorization for its drug to treat screwworm, causing its stock price to rise.
Aug 11, 2026, 05:21 UTC
Zoetis Inc.'s stock price hit a new 52-week low during mid-day trading on Monday after Piper Sandler lowered its price target from $90.00 to $80.00.
Source:Aug 6, 2026, 11:32 UTC
Zoetis announced a quarterly dividend of $0.53 per share, an increase of $0.03 from the prior year's quarter.
Source:Aug 6, 2026, 11:00 UTC
Zoetis Inc. reported its financial results for the second quarter of 2026, with revenue of $2.5 billion, flat compared to the same quarter of 2025, and net income of $691 million, or $1.65 per diluted share, down 5% on a reported basis.
Jul 22, 2026, 11:30 UTC
Zoetis Inc. launched Portela (relfovetmab) in Canada and the European Union.
Source:Jul 16, 2026, 14:09 UTC
A securities class action lawsuit has been filed against Zoetis Inc. in connection with alleged misrepresentations about its companion animal growth narrative.
Source:Jul 15, 2026, 12:30 UTC
Zoetis launched Lenivia (izenivetmab injection) in Canada and the European Union.
Source:Jul 14, 2026, 13:00 UTC
Zoetis Inc. announced an agreement to acquire VitalRADS, a veterinary teleradiology services platform.
Jul 7, 2026, 11:00 UTC
The European Commission granted marketing authorization to Zoetis for Poulvac Procerta HVT-ND, a recombinant vector vaccine for chickens against Newcastle disease and Marek's disease.
Source:Jun 15, 2026, 14:31 UTC
Anterra Capital reached a $100 million first close for Fund III, targeting $200 million, with backing from Rabobank, Novo Holdings, and Zoetis among others.
Jun 3, 2026, 06:57 UTC
A class action lawsuit was filed against Zoetis Inc. for alleged securities law violations.